Novo Nordisk A/S (NYSE:NVO) Shares Sold by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 14.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 160,726 shares of the company’s stock after selling 26,945 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Novo Nordisk A/S were worth $11,161,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Strategic Investment Solutions Inc. IL raised its holdings in Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock valued at $27,000 after acquiring an additional 300 shares in the last quarter. Park Square Financial Group LLC acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at $29,000. Transce3nd LLC acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at $33,000. Kelly Lawrence W & Associates Inc. CA acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at $39,000. Finally, Mascagni Wealth Management Inc. acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at $40,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NVO has been the topic of several recent analyst reports. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Dbs Bank lowered shares of Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. BMO Capital Markets reiterated a “market perform” rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, Hsbc Global Res upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, April 28th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $112.00.

Novo Nordisk A/S Trading Up 1.4%

Novo Nordisk A/S stock opened at $70.70 on Wednesday. The company has a 50-day simple moving average of $68.61 and a 200-day simple moving average of $77.93. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.92. The firm had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.